18 Mar C3i Center
Posted at 16:52h
in
Louisa Petropoulos, Ph.D., CEO
April 11 | 11:45am | Salone dei Cavalieri, Section 2
Montreal, Canada
(Private)
C3i is a global full-service CDMO manufacturing from process development to phase 3 in EU, US and Canada with commercial manufacturing launch in 2024 without the need to tech transfer to a 2nd facility. C3i offers a unique model offering shared risk with innovative companies to help them advance through funding gaps. This unites the company and C3i with a common goal ensuring success.
- Strong process development team with diverse experience in cell manufacturing including CAR-T, TcR, B-cell, NK, MSC, IPSC, and allogeneic.
- viral & non-viral transduction
- CRISPR editing
- Strong scale-up and scale-out ability for commercial manufacturing
- High production success rate of ~99%
- Validated Qc testing in-house
- CAP-accredited immune monitoring and diagnostic testing services
- CRO services specializing in cell therapy clinical trials
- Attractive COGS (>25% cheaper than other US/EU CDMOs)
- Partnership with leading research hospital and access to KOLs for protocol development, clinical trial launch, and DSMB review.
- C3i and company work as a team while keeping the patient in mind.
